HectorRNavaMD

General Surgery • Buffalo, NY

Professor, Surgery, SUNY Buffalo School of Medicine & Biomedical

Join to view full profile

Dr. Nava is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nava's full profile

Already have an account?

Office
Elm And Carlton St
Roswell Park Cancer Inst
Buffalo, NY 14263
Phone+1 716-845-2300

Fax+1 716-845-2320

Education & Training

University at BuffaloFellowship, Hematology and Medical Oncology, 1975 - 1976
University at BuffaloResidency, Surgery, 1974 - 1975
University at BuffaloResidency, Surgery, 1970 - 1974
CHRISTUS Health/Texas A&M College of Medicine/Spohn HospitalInternship, Transitional Year, 1967 - 1968
Universidad Autonoma de Nuevo LeonClass of 1967

Certifications & Licensure

NY State Medical License 1975 - 2025

Clinical Trials

Photodynamic Therapy in Treating Patients With Early Esophageal Cancer Start of enrollment: 1995 Oct 01
Completed
Phase 2
Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors Start of enrollment: 1997 Jan 01
Completed
Phase 1, Phase 2
Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer Start of enrollment: 2004 Feb 01
Completed
Phase 2
Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus Start of enrollment: 2000 Aug 01
Completed
Phase 1
Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus Start of enrollment: 2003 Mar 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

11 citations
Complete pathologic response is independent of the timing of esophagectomy following neoadjuvant chemoradiation for esophageal cancer
Smit Singla, Emmanuel Gabriel, Raed M. Alnaji, William Du, Kristopher Attwood
Journal of Gastrointestinal Oncology. 2018-02-01
36 citations
Pathologic Complete Response Is an Independent Predictor of Improved Survival Following Neoadjuvant Chemoradiation for Esophageal Adenocarcinoma
Raed M. Alnaji, William Du, Emmanuel Gabriel, Smit Singla, Kristopher Attwood
Journal of Gastrointestinal Surgery. 2016-06-03
36 citations
Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal...
Moshim Kukar, Raed M. Alnaji, Feraas Jabi, Timothy A. Platz, Kristopher Attwood
JAMA Surgery. 2015-06-01